Home > Products > Flexor
Share Print This Page

Flexor (Cyclobenzaprine)
Therapeutic Group: Skeletal Muscle Relaxant
Presentation
Flexor

Flexor 5: Each tablet contains Cyclobenzaprine Hydrochloride USP 5 mg.

Flexor 10: Each tablet contains Cyclobenzaprine Hydrochloride USP 10 mg.

Descriptions
Cyclobenzaprine Hydrochloride relieves skeletal muscle spasm of local origin without interfering with muscle function.
Indications
Flexor is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.

Dosage & Administration
The usual dose is 5-10 mg three times daily given by mouth. The daily dose should not exceed 60 mg. Treatment for more than 2 or 3 weeks is not recommended.
Dose in elderly: Therapy with Flexor in the elderly should be initiated with a 5 mg dose and titrated slowly upward.
Dose in hepatic impairment: Flexor should be used with caution in subjects with mild hepatic impairment starting with the 5 mg dose and titrating slowly upward. The use of Flexor in subjects with moderate to severe impairment is not recommended.
Pediatric Use: Safety and effectiveness of Cyclobenzaprine Hydrochloride in pediatric patients below 15 years of age have not been established.
Side Effects
The adverse reactions reported most frequently with Cyclobenzaprine Hydrochloride are drowsiness, dry mouth and dizziness. The incidence of these common adverse reactions is lower in the surveillance program than in the controlled clinical studies.
Precautions
Because of its atropine-like action, Cyclobenzaprine Hydrochloride should be used with caution in patients with a history of urinary retention, angle-closure glaucoma, increased intraocular pressure, and in patients taking anticholinergic medication.
Contraindications
Hypersensitivity to any component of this product. Concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation.
Hyperpyretic crisis seizures, and deaths have occurred in patients receiving Cyclobenzaprine (or structurally similar tricyclic antidepressants) concomitantly with MAO inhibitor drugs.
Acute recovery phase of myocardial infarction, and patients with arrhythmias, heart block or conduction disturbances, or congestive heart failure. Hyperthyroidism.
Use in Pregnancy & Lactation
Pregnancy: Pregnancy category B. This drug should be used during pregnancy only if clearly needed.

Lactation: Caution should be exercised when Cyclobenzaprine Hydrochloride is administered to a nursing mother.
Overdose
Although rare, deaths may occur from over dosage with Cyclobenzaprine Hydrochloride. Signs and symptoms of toxicity may develop rapidly after Cyclobenzaprine overdose; therefore, hospital monitoring is required as soon as possible.
Commercial Packaging
Flexor 5: Each box contains 10 blister strips of 10 tablets.
Flexor 10: Each box contains 10 blister strips of 10 tablets.
Others

Products from the same therapeutic group
Skeletal Muscle Relaxant
Danlene
Dantrolene Sodium 25 mg Capsule
Flexifen
Baclofen BP
Flexor
Cyclobenzaprine Hydrochloride
Myolax
Tolperisone Hydrochloride
Myolax Plus
Tolperisone Hydrochloride & Lidocaine Hydrochloride